Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/7/2025

TENS for Muscle Tightness Relief

Guideline-Based Recommendations

  • The American College of Rheumatology/Arthritis Foundation strongly recommends against TENS for knee and/or hip osteoarthritis, citing low-quality studies with small sample sizes, variable controls, and demonstrated lack of benefit 1, 2
  • The evidence base for TENS in musculoskeletal conditions has been consistently poor, making cross-trial comparisons difficult and failing to show clinically meaningful improvements 1, 2

Limited Short-Term Evidence for Acute Pain

  • The American College of Physicians and American Academy of Family Physicians found low-certainty evidence that TENS reduced acute musculoskeletal pain at less than 2 hours (mean reduction of 1.94 cm on a 10-cm pain scale compared to placebo) 3
  • This short-term pain reduction does not translate to relief of muscle tightness specifically, and the evidence quality is insufficient to support routine clinical use 3

Context-Specific Considerations

  • The American Society of Anesthesiologists recommends TENS only as part of multimodal pain management for chronic back pain, not as standalone therapy 4, 5
  • TENS should never be used as monotherapy but must be combined with exercise, physical therapy, and medications 5
  • Evidence is inadequate for acute or subacute low back pain according to the American College of Physicians 5

Clinical Algorithm

  • Do not use TENS as first-line or standalone therapy based on strong guideline recommendations against its use 1, 2
  • If TENS is used despite limited evidence, it should only be part of multimodal therapy including exercise and physical therapy 4, 5
  • If TENS is used, it should only be for chronic (not acute) conditions 5
  • If TENS is used, it should be with realistic expectations of minimal benefit 1, 2

Important Caveats

  • Approximately one-third of patients experience mild skin irritation at electrode sites 4, 5
  • Insurance coverage typically requires failed conventional therapies first and documented functional improvement 6